BEDFORD, Mass., July 03, 2025 - Anika Therapeutics, Inc. $(ANIK)$ has announced the granting of non-statutory stock options to a newly hired non-executive employee as part of their compensation package. On July 1, 2025, Anika issued options for 2,500 shares of common stock at an exercise price of $10.53 per share, reflecting the closing price on the Nasdaq Global Select Market on the grant date. This grant, made under the Anika Therapeutics, Inc. 2021 Inducement Plan and approved by the compensation committee, aims to provide material inducement for the employee's acceptance of their role. The options will vest over three years, with one-third vesting each year, contingent on continuous service. The options are set to expire ten years from the grant date unless terminated earlier under specific terms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.